Protalix BioTherapeutics (PLX.TA) stock price, revenue, and financials

Protalix BioTherapeutics market cap is ₪492.1 m, and annual revenue was $54.69 m in FY 2019

₪492.1 M

PLX.TA Mkt cap, 20-Jan-2021

$10.8 M

Protalix BioTherapeutics Revenue Q3, 2020
Protalix BioTherapeutics Gross profit (Q3, 2020)7.9 M
Protalix BioTherapeutics Gross profit margin (Q3, 2020), %73.4%
Protalix BioTherapeutics Net income (Q3, 2020)-4.4 M
Protalix BioTherapeutics EBIT (Q3, 2020)-2.6 M
Protalix BioTherapeutics Cash, 30-Sept-202013.5 M
Protalix BioTherapeutics EV542.1 M

Protalix BioTherapeutics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

764.0k1.1m3.9m26.1m3.7m3.6m2.3m2.3m2.4m2.4m4.4m3.8m679.0k1.8m4.7m2.9m6.4m7.5m4.6m2.0m663.0k21.6m11.0m10.8m

Cost of goods sold

132.0k220.0k1.3m3.3m2.4m971.0k1.3m1.6m1.6m1.8m2.4m2.0m2.3m523.0k1.7m4.2m2.1m5.5m6.1m2.9m2.2m1.9m2.0m2.7m3.2m3.4m1.8m2.9m

Gross profit

632.0k912.0k2.5m22.8m1.4m2.6m946.0k697.0k820.0k598.0k2.0m1.7m156.0k94.0k422.0k801.0k835.0k1.5m1.6m(177.0k)(1.3m)18.2m9.1m7.9m

Gross profit Margin, %

83%81%66%87%36%73%42%31%34%25%45%46%23%5%9%28%13%19%36%(9%)(189%)84%83%73%

R&D expense

8.8m9.3m8.8m10.5m8.3m7.8m8.0m7.1m

General and administrative expense

1.8m1.5m1.6m3.5m2.2m2.1m2.2m

Operating expense total

9.1m9.4m8.5m12.4m8.6m7.4m8.6m7.4m6.5m8.1m7.5m7.0m6.3m8.0m10.0m7.1m7.2m11.6m9.2m8.9m9.4m12.7m13.5m11.4m10.5m

EBIT

(13.9m)(8.8m)(6.1m)9.6m(5.6m)(4.4m)(6.9m)(5.6m)(5.4m)(6.2m)(4.8m)(4.5m)(2.8m)(7.9m)(9.9m)(6.6m)(6.4m)(10.8m)(7.8m)(7.3m)(9.6m)(14.0m)(5.5m)(5.8m)(1.5m)4.7m(2.2m)(2.6m)

EBIT margin, %

(1815%)(774%)(157%)37%(149%)(124%)(305%)(247%)(225%)(259%)(110%)(118%)(1158%)(561%)(142%)(220%)(170%)(103%)(161%)(477%)(2106%)22%(20%)(24%)

Interest expense

57.0k102.0k672.0k1.8m1.1m599.0k1.0m662.0k805.0k642.0k52.8m11.3m3.7m2.1m1.7m1.6m1.7m1.9m2.0m

Interest income

202.0k49.0k28.0k43.0k17.0k242.0k96.0k268.0k1.6m40.0k8.0k132.0k75.0k230.0k190.0k3.0k34.0k203.0k38.0k118.0k

Net Income

(13.7m)(8.9m)(5.9m)9.6m(5.5m)(4.3m)(6.8m)(5.7m)(6.1m)(8.0m)(6.0m)(5.1m)(3.8m)(8.6m)(10.9m)(7.3m)(59.1m)450.0k(11.4m)(9.4m)(11.3m)(15.5m)(7.3m)(7.7m)(3.6m)1.7m(4.1m)(4.4m)

Protalix BioTherapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

44.1m34.6m45.6m59.3m50.2m41.9m33.1m91.4m71.1m60.3m48.0m43.2m34.2m66.7m54.6m51.3m48.0m34.5m33.5m41.3m28.3m41.9m30.4m25.1m21.4m14.2m4.8m13.5m

Accounts Receivable

1.7m2.3m815.0k1.5m4.0m1.7m2.0m2.1m2.1m2.0m1.8m1.9m4.6m1.5m2.1m2.7m3.0m7.3m4.8m5.2m4.9m8.6m7.3m8.7m8.9m5.3m3.1m

Prepaid Expenses

2.9m2.3m2.7m2.9m5.1m1.0m3.5m4.1m2.7m2.6m2.5m2.6m1.7m2.2m2.8m

Inventories

537.0k427.0k263.0k1.0m2.1m5.8m7.2m7.6m7.1m6.8m6.9m6.4m6.3m5.7m6.1m4.9m7.1m7.1m7.5m7.0m7.0m8.0m6.7m7.0m7.5m9.5m11.1m13.3m

Current Assets

51.2m40.3m49.8m65.9m59.6m52.9m45.9m105.2m82.4m71.2m59.6m53.9m47.9m76.3m67.6m59.6m61.5m48.9m51.2m55.7m43.1m57.3m47.3m41.6m40.4m57.8m54.2m60.3m

PP&E

18.9m18.5m17.5m17.3m16.7m15.7m15.0m14.3m12.4m11.8m10.8m10.4m10.0m9.3m9.5m9.1m8.5m8.2m8.0m7.3m6.9m6.6m6.1m5.9m5.6m5.0m4.8m4.6m

Total Assets

71.9m60.8m68.5m84.3m77.4m69.9m62.3m121.2m96.7m84.8m72.0m66.0m59.5m87.3m78.9m70.5m71.9m59.0m61.1m64.8m51.7m67.2m61.0m55.2m53.7m82.9m71.7m72.3m

Accounts Payable

5.8m5.0m4.6m4.5m4.4m3.8m3.9m3.3m3.6m3.6m5.2m4.3m4.1m3.9m3.8m4.0m6.0m7.9m8.7m4.9m6.0m4.4m5.9m6.7m7.8m9.4m6.7m8.4m

Short-term debt

5.9m5.9m5.4m5.4m5.5m

Current Liabilities

20.3m18.3m17.7m21.3m20.4m24.4m26.6m25.2m27.2m24.4m26.5m25.5m22.9m9.3m11.5m10.3m20.3m19.1m26.6m21.5m15.1m14.6m27.0m26.0m33.3m47.6m42.4m43.9m

Long-term debt

4.5m4.7m4.7m2.8m2.7m376.0k66.9m67.3m67.4m67.6m67.7m67.8m67.9m68.0m68.1m113.2m53.6m53.6m46.1m46.7m47.3m53.2m54.0m54.7m56.3m57.1m58.1m

Non-Current Liabilities

60.3m59.9m57.2m55.1m52.2m51.8m47.7m112.6m109.3m108.1m106.7m105.6m105.2m75.4m75.4m75.2m120.0m60.6m60.5m82.7m86.2m117.6m93.9m96.7m91.3m66.1m64.1m61.7m

Total Debt

4.5m4.7m4.7m2.8m2.7m376.0k66.9m67.3m67.4m67.6m67.7m67.8m67.9m68.0m68.1m113.2m53.6m59.5m52.0m46.7m47.3m53.2m54.0m54.7m61.7m62.6m63.5m

Total Liabilities

80.6m78.2m74.9m76.4m72.6m76.2m74.3m137.9m136.4m132.5m133.2m131.1m128.0m84.7m86.8m85.6m140.3m79.7m87.1m104.2m101.3m132.2m120.9m122.7m124.6m113.8m106.5m105.6m

Retained Earnings

337.6m341.0m

Total Equity

(8.7m)(17.4m)(6.5m)7.9m4.8m(6.3m)(12.0m)(16.7m)(39.8m)(47.7m)(61.2m)(65.1m)(68.5m)2.7m(8.0m)(15.1m)(68.5m)(20.7m)(26.1m)(39.4m)(49.6m)(65.0m)(59.9m)(67.5m)(70.8m)(30.9m)(34.8m)(33.3m)

Debt to Equity Ratio

-0.5 x-0.3 x0.6 x0.6 x-0.4 x0 x-4 x-1.7 x-1.4 x-1.1 x-1 x-1 x25.6 x-8.5 x-4.5 x-1.7 x-2.6 x-2.3 x-1.3 x-0.9 x-0.7 x-0.9 x-0.8 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0 x0 x0 x0.6 x0.7 x0.8 x0.9 x1 x1.1 x0.8 x0.9 x1 x1.6 x0.9 x1 x0.8 x0.9 x0.7 x0.9 x1 x

Financial Leverage

-8.3 x-3.5 x-10.6 x10.7 x16.2 x-11.1 x-5.2 x-7.3 x-2.4 x-1.8 x-1.2 x-1 x-0.9 x32.9 x-9.9 x-4.7 x-1 x-2.9 x-2.3 x-1.6 x-1 x-1 x-1 x-0.8 x-0.8 x-2.7 x-2.1 x-2.2 x

Protalix BioTherapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(18.7m)(27.6m)(5.9m)3.7m(1.7m)(4.3m)(11.2m)(16.9m)(13.5m)(21.5m)(6.0m)(11.0m)(14.9m)(8.6m)(19.5m)(26.7m)(59.1m)(58.7m)(70.1m)(9.4m)(20.7m)(36.2m)(7.3m)(15.0m)(18.6m)1.7m(2.5m)(6.9m)

Depreciation and Amortization

616.0k1.2m1.8m516.0k1.0m1.5m492.0k986.0k1.5m430.0k846.0k1.3m405.0k784.0k1.2m376.0k710.0k1.0m

Accounts Receivable

2.0m2.8m1.3m(462.0k)(2.1m)(42.0k)(406.0k)(798.0k)(397.0k)(578.0k)(735.0k)(41.0k)(3.2m)(1.2m)(5.0m)(1.4m)(3.1m)(3.5m)(6.5m)(3.5m)(4.0m)(3.7m)(3.6m)(2.8m)(4.8m)(4.1m)(1.6m)783.0k

Inventories

652.0k762.0k16.0k(750.0k)(1.8m)(1.7m)(3.2m)(3.5m)822.0k1.1m(212.0k)299.0k328.0k30.0k(300.0k)907.0k(1.9m)(1.8m)(2.2m)814.0k855.0k(126.0k)1.9m1.6m1.0m(1.3m)(2.9m)(5.1m)

Accounts Payable

4.8m4.4m(242.0k)2.1m369.0k(3.0m)(3.0m)(5.4m)180.0k(1.7m)(893.0k)(1.9m)(4.4m)(470.0k)1.3m367.0k2.4m5.4m8.7m(1.0m)(1.3m)(1.8m)864.0k1.5m4.9m2.6m309.0k3.3m

Cash From Operating Activities

(8.8m)(17.0m)(6.3m)6.8m(1.2m)(9.6m)(17.7m)(25.9m)(14.9m)(24.4m)(6.4m)(11.8m)(20.4m)(9.6m)(21.3m)(24.8m)(8.4m)(17.0m)(27.6m)(9.4m)(17.4m)(3.7m)(7.3m)(12.4m)(15.7m)(7.1m)(15.0m)(18.6m)

Purchases of PP&E

(4.0m)(5.0m)(810.0k)(1.0m)(1.8m)(642.0k)(1.3m)(1.7m)(371.0k)(617.0k)(99.0k)(332.0k)(460.0k)(251.0k)(575.0k)(732.0k)(220.0k)(543.0k)(681.0k)(249.0k)(394.0k)(498.0k)(170.0k)(207.0k)(599.0k)(66.0k)(278.0k)(380.0k)

Cash From Investing Activities

(4.1m)(5.1m)(852.0k)(1.1m)(1.9m)(689.0k)(1.4m)(1.8m)(565.0k)(832.0k)(99.0k)(347.0k)(516.0k)(293.0k)(659.0k)(725.0k)(283.0k)(969.0k)(1.1m)(328.0k)(447.0k)(675.0k)(371.0k)(466.0k)(912.0k)(35.1m)(35.3m)(27.5m)

Cash From Financing Activities

20.9m20.9m25.6m26.6m26.4m30.0k67.0m31.0k43.0k534.0k534.0k(6.7m)(11.0m)(1.4m)(4.8m)(4.8m)38.6m37.3m41.8m

Net Change in Cash

8.2m(1.3m)18.6m32.3m23.2m(10.2m)(18.9m)39.4m(15.3m)(26.1m)(6.8m)(11.5m)(20.5m)(9.7m)(21.7m)(25.1m)(15.3m)(28.7m)(29.8m)(9.8m)(22.8m)(9.3m)(7.4m)(12.7m)(16.4m)(3.6m)(12.9m)(4.3m)

Interest Paid

1.6m1.6m3.1m1.6m1.6m3.1m432.0k2.3m2.6m145.0k2.4m2.4m2.2m2.2m

Protalix BioTherapeutics Ratios

USDQ2, 2011

Debt/Equity

-0.5 x

Debt/Assets

0.1 x

Financial Leverage

-8.3 x